![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20200430014853048-0554:S0924933800217306:S0924933800217306_fig1.png?pub-status=live)
Fig. 1
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20200430014853048-0554:S0924933800217306:S0924933800217306_fig2.png?pub-status=live)
Fig. 2
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20200430014853048-0554:S0924933800217306:S0924933800217306_fig3.png?pub-status=live)
Fig. 3
10 September 2024: Due to technical disruption, we are experiencing some delays to publication. We are working to restore services and apologise for the inconvenience. For further updates please visit our website: https://www.cambridge.org/universitypress/about-us/news-and-blogs/cambridge-university-press-publishing-update-following-technical-disruption
Published online by Cambridge University Press: 23 March 2020
There are many jobs that offer advantages of treatment with long-acting injectable in psychosis.
To know the changes in the different variables after the start of paliperidone palmitate (PP).
We performed a descriptive and retrospective study. Were evaluated patients who received maintenance therapy with PP during 48 months.
The sample was composed of 29 patients: 72.4% men and 27.6% women. Average age of 46.21 years. In Figures 1, 2 and 3 show data obtained in relation to compliance with treatment, relapse, maintenance dose, number of admissions and visits to emergency departments respectively.
The administration of PP is associated with a higher level of compliance with treatment. The patients presented a lower number of relapses, hospitalizations and visits to the emergency room. The maintenance dose more used is 150 mg.
The authors have not supplied their declaration of competing interest.
Fig. 1
Fig. 2
Fig. 3
Fig. 1
Fig. 2
Fig. 3
Comments
No Comments have been published for this article.